SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29:1036-1042.
  • 2
    Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29:1043-1049.
  • 3
    Feske SK. Posterior reversible encephalopathy syndrome: a review. Semin Neurol. 2011;31:202-215.
  • 4
    Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494-500.
  • 5
    Casey SO, Sampaio RC, Michel E, et al. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol. 2000;21:1199-1206.
  • 6
    Morris EB, Laningham FH, Sandlund JT, et al. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer. 2007;48:152-159.
  • 7
    Lucchini G, Grioni D, Colombini A, et al. Encephalopathy syndrome in children with hemato-onocological disorders is not always posterior and reversible. Pediatr Blood Cancer. 2008;51:629-633.
  • 8
    de Laat P, te Winkel ML, Devos AS, Catsman-Berrevoets CE, Pieters R, van den Heuvel-Eibrink. Posterior reversible encephalopathy syndrome in childhood cancer. Ann Oncol. 2011;22:472-478.
  • 9
    Yu A, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-1334.
  • 10
    Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31A:261-267.
  • 11
    Yu AL, Batova A, Alvarado C, Rao VJ, Castelberry RP. Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG phase II study [abstract]. Am Soc Clin Oncol. 1997;16. Abstract 513a.
  • 12
    Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169-2180.
  • 13
    Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group study. J Clin Oncol. 2001;18:4077-4085.
  • 14
    Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol. 2009;27:85-91.
  • 15
    Cheung N-KV, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430-1440.
  • 16
    Cheung N-KV, Kushner BH, Yeh SJ, Larson SM. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study. Int J Oncol. 1998;12:1299-1306.
  • 17
    Cheung N-KV, Kushner BH, Cheung IY, et al. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16:3053-3060.
  • 18
    Kushner BH, Kramer K, Cheung N-KV. Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189-4194.
  • 19
    Cheung N-KV, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2006;24:2885-2890.
  • 20
    Kushner BH, Kramer K, Modak S, Cheung N-KV. Successful multi-fold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol. 2011;29:1168-1174.
  • 21
    Cheung N-KV, Cheung IY, Kushner BH, Ostrovnaya I, Kramer K, Modak S. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor and 13-cis-retinoic acid is effective against chemoresistant marrow MRD among high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30:3264-3270.
  • 22
    Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165-1173.
  • 23
    Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neuro-Oncol. 2010;97:409-418.
  • 24
    Won SC, Kwon SY, Han JW, Choi SY, Lyu CJ. Posterior reversible encephalopathy syndrome in childhood with hematologic/oncologic diseases. J Pediatr Hematol Oncol. 2009;31:505-508.
  • 25
    Handgretinger R, Baader P, Dopfer R, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother. 1992;35:199-204.
  • 26
    Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer. 1997;80:317-333.
  • 27
    Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol. 2004;22:3549-3557.
  • 28
    Simon T, Hero B, Faldum A, et al. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin Padiatr. 2005;217:147-152.
  • 29
    Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL-2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res. 2006;12:1750-1759.
  • 30
    Shusterman S, London WB, Gillies SD, et al. Antitumor activity of Hu14.18-IL-2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010;28:4969-4975.
  • 31
    Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibody Hybridom. 1992;3:19-24.
  • 32
    Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res. 1992;52:4342-4347.
  • 33
    Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol. 1994;12:184-193.
  • 34
    Murray JL, Kleinerman ES, Jia S, et al. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother. 1996;19:206-217.
  • 35
    Albertini MR, Hank JA, Schiller JH, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin-2 for melanoma patients. Clin Cancer Res. 1997;3:1277-1288.
  • 36
    King DM, Albertini MR, Schalch H, et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004;22:4463-4473.
  • 37
    Kastrup O, Diener HC. TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome. J Neurol. 2008;255:452-453.
  • 38
    Haddock R, Garrick V, Horrocks I, Russell RK. A case of posterior reversible encephalopathy syndrome in a child with Crohn's disease treated with infliximab. J Crohns Colitis. 2011;5:623-627.
  • 39
    Parsons K, Bernhardt B, Strickland B. Targeted immunotherapy for high-risk neuroblastoma—the role of monoclonal antibodies. Ann Pharmacol. 2013;47:210-218.
  • 40
    Pavlakis SG, Frank Y, Chusid R. Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: 3 names for an old syndrome. J Child Neurol. 1999;14:277-281.
  • 41
    Flandin I, Hartmann O, Michon M, et al. Impact of TBI on late effects in children treated by megatherapy for stage IV neuroblastoma. A study of the French Society of Pediatric Oncology. Int J Radiat Oncol Biol Phys. 2006;64:1424-1431.
  • 42
    Trahair TN, Vowels MR, Johnston K, et al. Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant. 2007;40:741-746.
  • 43
    Hobbie WL, Moshang T, Carlson CA, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer. 2008;51:679-683.